AYTU BioPharma financials
$2.20+1.38%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Jun 30 | FY25 Jun 30 | FY24 Jun 30 | FY23 Jun 30 | FY22 Jun 30 | FY21 Jun 30 | FY20 Jun 30 | FY19 Jun 30 | FY18 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $57.6M | $66.4M | $65.2M | $107.4M | $96.7M | $65.6M | $27.6M | $7.3M | $3.7M |
| Gross profit | $36.8M | $45.8M | $49.1M | $66.6M | $52.3M | $29.2M | $19.4M | $5.1M | $1.6M |
| Gross margin | 64.0% | 69.0% | 75.3% | 62.0% | 54.1% | 44.5% | 70.0% | 69.9% | 44.0% |
| Operating income | -$8.3M | -$7.8M | -$1.6M | -$17.1M | -$109.9M | -$56.0M | -$21.1M | -$16.8M | -$19.7M |
| Net income | -$14.3M | -$13.6M | -$15.8M | -$17.1M | -$108.8M | -$58.3M | -$13.6M | -$27.1M | -$10.2M |
| Net margin | −24.8% | −20.4% | −24.3% | −15.9% | −112.5% | −88.8% | −49.3% | −370.6% | −278.3% |
| Diluted EPS | $-1.16 | $-2.16 | $-2.86 | $-5.11 | $-74.01 | $-69.60 | $-60.20 | $-696.00 | $-3062.00 |
| EBITDA | -$4.4M | $7.9M | $7.3M | -$3.5M | -$26.0M | -$29.0M | -$12.2M | -$14.1M | -$15.3M |
| Operating cash flow | $3.3M | -$1.9M | -$1.4M | -$5.1M | -$28.8M | -$26.0M | -$17.9M | -$13.8M | -$15.9M |
| Free cash flow | $3.3M | -$2.2M | -$1.7M | -$5.1M | -$28.8M | -$28.3M | -$17.9M | -$14.4M | -$16.4M |
| Diluted shares | 12.3M | 6.3M | 5.5M | 3.3M | 1.5M | 0.8M | 0.2M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $26.3M | $31.0M | $20.0M | $23.0M | $19.4M | $49.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $17.0M | $21.8M | $15.1M | $16.4M | $18.2M | $24.8M |
| Total assets | $105.0M | $124.2M | $118.1M | $136.5M | $137.6M | $265.7M |
| Total liabilities | $69.7M | $105.2M | $90.4M | $97.1M | $93.3M | $128.1M |
| Shareholders' equity | $35.3M | $19.0M | $27.7M | $39.4M | $44.3M | $137.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology